Status:
COMPLETED
Immunohistochemical Study of Chordomas to Improve Their Diagnosis and Prognosis Care
Lead Sponsor:
Centre Hospitalier Universitaire de Saint Etienne
Conditions:
Chordoma
Eligibility:
All Genders
Brief Summary
Chordomas are very rare malignant tumors, chemo-resistant with high propensity for recurrence. The role of immunotherapy in these patients remains largely unexplored while PD-L1 and CD8 status in the ...
Detailed Description
Retrospective, non-interventional study. A series of chordomas will be analyzed for detailed histologic features and for various immunohistochemical factors and results will be compared with clinical ...
Eligibility Criteria
Inclusion
- Patients diagnosed with chordoma
- Sufficient histological material available
- Tumor expression of brachyury
Exclusion
- \- Insufficient histological material
Key Trial Info
Start Date :
April 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 1 2020
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT04486820
Start Date
April 1 2020
End Date
July 1 2020
Last Update
July 27 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU de Saint-Etienne
Saint-Etienne, France